依帕司他联合弥可保治疗糖尿病周围神经病变疗效观察

Evaluation of Epalrestat combined with Methycobal in treating patients with diabetic peripheral neuropathy

目的探讨依帕司他联合弥可保在治疗糖尿病周围神经病变中的临床价值和安全性。方法选择我院2007～2009年收治的糖尿病周围神经病变患者78例,随机分为观察组和对照组,每组各39例,对照组给予弥可保治疗,初始剂量0.5 mg/次,1次/d,肌内注射,4周后改口服弥可保0.5 mg/次,3次/d,服用8周;观察组在此基础上给予依帕司他片50 mg/次,3次/d,疗程为12周。分别于治疗前后比较两组患者的神经传导速度、总症状积分(TSS)、下肢神经损害(NIS-LL)评分、神经症状改变(NSC)评分。结果观察组治疗后总有效率达92.3%,显著高于对照组(59.0%)(P<0.05);治疗12周后两组患者神经传导速度均有所改善(P<0.05),但观察组改善幅度显著好于对照组(P<0.05),且观察组在TSS、NSC和NIS-LL评分方面显著好于对照组(P<0.05)。结论依帕司他联合弥可保治疗糖尿病周围神经病变效果显著,能有效改善患者周围神经病变症状,提升神经传导速度,且安全。

Objective To investigate the clinical effect of Epalrestat combined with Methycobal in treating patients with diabetic peripheral neuropathy. Methods 78 patients with diabetic peripheral neuropathy were selected and divided into two groups for each 39 cases, patients in control group were given Methycobal intramuscular injection with the dose of 0.5 mg/d for 4 weeks, and methycobal were given by oral for 3 times per day and each for 0.5 mg, other patients in observation group were given Epalrestat by oral for 3 times per day and each for 50 mg on the basis of control group, the nerve con- duction velocity, TSS, NIS-LL and NSC were compared. Results The total efficiency rate of observation group was 92.3%, significantly better than 59.0% of control group （P 〈 0.05）, and the nerve conduction velocity and scores of TSS, NIS-LL and NSC of observation group were also better than control group after treatment （P 〈 0.05）. Conclusion The method of Epalrestat combined with Methycobal has a good effect, can improve the symptoms of peripheral neuropathy effectively and also has a virtue of safety.